GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » Beneish M-Score

TELA Bio (TELA Bio) Beneish M-Score : -2.57 (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is TELA Bio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for TELA Bio's Beneish M-Score or its related term are showing as below:

TELA' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.4   Max: -2.17
Current: -2.57

During the past 7 years, the highest Beneish M-Score of TELA Bio was -2.17. The lowest was -2.83. And the median was -2.40.


TELA Bio Beneish M-Score Historical Data

The historical data trend for TELA Bio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio Beneish M-Score Chart

TELA Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - -2.83 -2.17 -2.22 -2.57

TELA Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.22 -2.37 -2.33 -2.47 -2.57

Competitive Comparison of TELA Bio's Beneish M-Score

For the Medical Devices subindustry, TELA Bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TELA Bio's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TELA Bio's Beneish M-Score falls into.



TELA Bio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TELA Bio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.042+0.528 * 0.9515+0.404 * 0.8294+0.892 * 1.4113+0.115 * 1.7022
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9251+4.679 * -0.108151-0.327 * 0.9552
=-2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $9.74 Mil.
Revenue was 16.998 + 15.052 + 14.494 + 11.909 = $58.45 Mil.
Gross Profit was 11.624 + 10.389 + 10.201 + 7.898 = $40.11 Mil.
Total Current Assets was $71.73 Mil.
Total Assets was $78.05 Mil.
Property, Plant and Equipment(Net PPE) was $3.94 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.81 Mil.
Selling, General, & Admin. Expense(SGA) was $74.57 Mil.
Total Current Liabilities was $16.97 Mil.
Long-Term Debt & Capital Lease Obligation was $40.52 Mil.
Net Income was -12.89 + -10.957 + -10.79 + -12.027 = $-46.66 Mil.
Non Operating Income was 0.733 + 0.558 + 0.87 + 0.473 = $2.63 Mil.
Cash Flow from Operations was -11.051 + -6.968 + -11.264 + -11.574 = $-40.86 Mil.
Total Receivables was $6.62 Mil.
Revenue was 11.622 + 11.159 + 10.406 + 8.231 = $41.42 Mil.
Gross Profit was 8.176 + 7.319 + 6.55 + 4.999 = $27.04 Mil.
Total Current Assets was $62.45 Mil.
Total Assets was $67.86 Mil.
Property, Plant and Equipment(Net PPE) was $2.91 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.19 Mil.
Selling, General, & Admin. Expense(SGA) was $57.11 Mil.
Total Current Liabilities was $12.40 Mil.
Long-Term Debt & Capital Lease Obligation was $39.92 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(9.737 / 58.453) / (6.621 / 41.418)
=0.166578 / 0.159858
=1.042

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(27.044 / 41.418) / (40.112 / 58.453)
=0.652953 / 0.686227
=0.9515

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (71.726 + 3.938) / 78.048) / (1 - (62.447 + 2.909) / 67.855)
=0.030545 / 0.036829
=0.8294

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=58.453 / 41.418
=1.4113

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.187 / (1.187 + 2.909)) / (0.808 / (0.808 + 3.938))
=0.289795 / 0.170249
=1.7022

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(74.568 / 58.453) / (57.114 / 41.418)
=1.275692 / 1.378966
=0.9251

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((40.515 + 16.967) / 78.048) / ((39.916 + 12.403) / 67.855)
=0.736495 / 0.771041
=0.9552

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-46.664 - 2.634 - -40.857) / 78.048
=-0.108151

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TELA Bio has a M-score of -2.57 suggests that the company is unlikely to be a manipulator.


TELA Bio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of TELA Bio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TELA Bio (TELA Bio) Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Executives
Gregory A. Firestone officer: Chief Business Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca officer: COO and CFO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Antony Koblish director, officer: Chief Executive Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p. other: See footnotes 1 and 2 280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp 10 percent owner QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p. 10 percent owner CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran director 0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Vincent J Burgess director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Douglas G Evans director 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355